The 503A and 503B distinction in Olympia's model
Olympia Pharmaceuticals, the 503B entity, is FDA-registered and licensed to compound large batches of medications for office use without a patient-specific prescription — a capability that most independent compounding pharmacies do not have. This is how Olympia provides sterility-tested, stability-studied products in batches above 250 vials with extended beyond-use dating. Clinics using 503B products receive office-use stock; patients are dosed from that stock in the clinic or dispensed by the provider.
Olympia Pharmacy, the 503A entity, provides patient-specific compounding — every order tied to a named patient prescription. Clinics submit through DrScript; Olympia compounds and ships directly to the patient overnight with discreet packaging. Both pathways flow through Olympia's own compounding operations. This single-compounder model gives clinics one relationship, one clinical liaison contact, and one formulary — but it means all orders route to Olympia rather than across multiple 503A partners.